YTENQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YTENQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Yield10 Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $1.399. Yield10 Bioscience's 10-Year median PS Ratio is 13.2666. Therefore, the Median PS Value for today is $18.56.
As of today (2025-03-27), Yield10 Bioscience's share price is $0.015. Yield10 Bioscience's Median PS Value is $18.56. Therefore, Yield10 Bioscience's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Yield10 Bioscience's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Yield10 Bioscience was 3.52. The lowest was 0.06. And the median was 1.73.
The historical data trend for Yield10 Bioscience's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yield10 Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 64.08 | 47.28 | 1.63 |
Yield10 Bioscience Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
30.89 | 30.52 | 1.63 | 9.57 | 18.56 |
For the Agricultural Inputs subindustry, Yield10 Bioscience's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Yield10 Bioscience's Price-to-Median-PS-Value falls into.
Yield10 Bioscience's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 1.399 | * | 13.2666 | |
= | 18.56 |
10-Year Median PS Ratio is 13.2666.
Yield10 Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yield10 Bioscience (OTCPK:YTENQ) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Yield10 Bioscience's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.015 | / | 18.56 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Yield10 Bioscience's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jack W Schuler | 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Richard William Hamilton | director | 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320 |
Willie Loh | director | C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801 |
Charles B Haaser | officer: VP Fin and CAO | |
Lynne H Brum | officer: VP Planning and Comms | 21 ERIE STREET, CAMBRIDGE MA 02139 |
Kristi Snell | officer: VP Research & CSO | C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801 |
Anthony J Sinskey | director | C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139 |
Sherri M. Brown | director | C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801 |
Oliver P Peoples | director, officer: Pres & CEO | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
Joseph H Shaulson | director | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Celeste Beeks Mastin | director | 21 ERIE STREET, CAMBRIDGE MA 02139 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Matthew Strobeck | director | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
William P Scully | 10 percent owner | C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 07-17-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By ACCESSWIRE • 11-08-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 04-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.